Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
Tesamorelin
A GHRH analog studied in lipodystrophy and GH-axis research.
- Half-life (approx.)
- ~26 min (approx., IV); subQ longer
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 2 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
Tesamorelin (TH9507) is an FDA-approved GHRH analog studied for HIV-associated lipodystrophy and visceral-fat reduction. It stimulates pulsatile GH release with a well-characterized pharmacokinetic profile in clinical literature. FDA-approved stabilized GHRH for HIV-associated visceral lipodystrophy research context.
Structure & identity
Stabilized GHRH analog — trans-3-hexenoic acid modified
- Chemical name
- (3E)-hex-3-enoylsomatoliberin
- Sequence / structure
- 44-amino-acid synthetic GHRH analogue with N-terminal trans-3-hexenoic acid modification
- Formula
- C221H366N72O67S
- Molecular weight
- 5136 g/mol
- CAS
- 218949-48-5
Status: FDA-approved (Egrifta).
Mechanism
Tesamorelin binds GHRH receptors on anterior pituitary somatotrophs, activating G-protein-coupled signaling that increases endogenous growth hormone synthesis and pulsatile release. Downstream GH stimulates hepatic IGF-1 and IGFBP-3 production. Lipolytic GH effects preferentially reduce visceral adipose in lipodystrophy models while generally sparing subcutaneous fat.
Stabilized GHRH analog stimulates pulsatile GH to reduce visceral adipose in lipodystrophy research. Trans-3-hexenoic acid modification improves GHRH stability versus native fragment.
Studies & clinical programs
HIV-associated lipodystrophy Phase 3(Phase 3)
HIV-infected adults on antiretroviral therapy with excess visceral adipose tissue
- Significant reduction in visceral adipose tissue on MRI versus placebo over treatment periods.
- Average ~15% reduction in excess visceral fat reported in pivotal analyses.
- Improved triglyceride and metabolic parameters in extension studies.
Source: Egrifta (tesamorelin) development program
Hepatic fat and body-composition substudies
HIV-positive cohorts with metabolic comorbidity
- Decreased liver fat fraction on imaging in 12-month substudies.
- CT-based muscle density and area changes documented in paraspinal and psoas muscle groups.
Source: Published lipodystrophy extension literature
Research models in literature
- HIV lipodystrophy trials
- Visceral adipose MRI endpoints
Literature highlights
- Stabilized GHRH analog reduces visceral adipose in HIV lipodystrophy trials (Egrifta).
- MRI visceral-fat and IGF-1 endpoints characterize metabolic effects.
- FDA-approved GHRH — compared with CJC and sermorelin in GH-axis research.
Combination research notes
GH-axis blends combine tesamorelin with ipamorelin (Tesa+IPA mix in this library).
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Sealed vial, refrigerated (2–8 °C) | Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial. |
| Reconstituted | Bacteriostatic water (0.9% benzyl alcohol), refrigerated | Most aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date. |
| Working aliquots | Pre-drawn syringes or microtubes, frozen (−20 °C) | Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 2 | 2 | 1000.0 | 10 | 25 | 50 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Typically reconstituted with 1–2 mL bacteriostatic water.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance